Strengths

Zoetis generates a 21.8% TTM ROIC, indicating superior capital efficiency versus large animal-health peers and supporting durable value creation.

Its companion-animal franchise and diversified species mix reduce dependence on any single end market, giving it steadier demand than more concentrated peers.

The company’s scale in veterinary pharmaceuticals and biologics strengthens commercial reach and R&D productivity, which typically exceeds smaller animal-health competitors.

A current ratio of 3.08 and quick ratio of 1.84 indicate ample liquidity, leaving Zoetis better positioned than more levered peers to absorb volatility.

Weaknesses

Net debt to EBITDA of 2.00 and debt-to-equity of 2.93 show meaningful leverage, leaving Zoetis less conservatively financed than the strongest peer balance sheets.

Cash conversion cycle of 339.7 days is structurally long, tying up working capital more than many peers and limiting near-term cash flexibility.

The business remains exposed to veterinary clinic utilization and pet-owner spending, so demand can soften faster than in more diversified healthcare peers.

Margin disclosure was not provided in the latest metrics, limiting visibility into whether Zoetis still outperforms peers on operating leverage.

Opportunities

Further penetration of parasiticides, dermatology, and pain franchises can deepen companion-animal share, where Zoetis already competes from a leading position versus peers.

International expansion offers room to lift revenue mix in underpenetrated markets, supporting growth beyond the more mature U.S. companion-animal base.

Pipeline execution in biologics and next-generation therapeutics can extend product life cycles, helping Zoetis defend share against smaller innovation-led competitors.

Operational improvements that shorten the cash conversion cycle would release working capital, improving flexibility relative to peers with similar scale.

Threats

Patent expirations and generic or biosimilar competition can pressure key products, eroding pricing power versus peers with fresher portfolios.

Veterinary labor shortages and clinic capacity constraints can slow procedure volumes, which would dampen demand across the animal-health category.

Input-cost inflation and reimbursement sensitivity can compress margins, especially if peers with lower cost bases defend share more aggressively.

A prolonged slowdown in pet spending or livestock health budgets would weigh on category growth, with more cyclical exposure than diversified healthcare peers.

Overall Score

Zoetis is structurally strong versus animal-health peers on scale, diversification, and capital efficiency, but leverage and working-capital intensity keep the overall profile below top-tier exceptional.